{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-005060","form_type":"8-K","ticker":"BPTH","cik":"0001133818","company_name":"BIO-PATH HOLDINGS, INC.","filed_at":"2024-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.407451+00:00","generated_at":"2026-06-03T22:44:56.093308+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Bio-Path expands global patent portfolio with new patents in Mexico, Australia, Japan","bullets":["Received newly issued patents in Mexico (IGF-1R inhibition), Australia (STAT3, IGF-1R, BCL2 inhibition), and Japan (liposomal formulation).","Portfolio now includes 5 issued US patents and 54 foreign patents covering 21 countries.","Expects six additional patent grants this year; 51 pending applications across six families.","Patents protect DNAbilize antisense platform and provide 20 years of exclusivity for new targets."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-005060","json":"https://secwatch.observer/filing/0001558370-24-005060.json","markdown":"https://secwatch.observer/filing/0001558370-24-005060.md","text":"https://secwatch.observer/filing/0001558370-24-005060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133818/000155837024005060/0001558370-24-005060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133818/000155837024005060/bpth-20240415x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T22:44:56.093308+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}